Ruxolitinib enhances gastric cancer to chemotherapy by suppressing JAK/STAT3 and inducing mitochondrial dysfunction and oxidative stress
Ruxolitinib demonstrates potential in overcoming chemoresistance in gastric cancer by targeting mitochondrial function, oxidative stress, and key survival pathways. These findings support further investigation into its clinical application as an adjunct therapy for chemoresistant gastric cancer.
Authors
- Cheng Chen (ORCID: https://orcid.org/0000-0002-9481-7809)
- Jun Zhou (ORCID: https://orcid.org/0009-0000-2512-9036)
- Yao Yang (ORCID: https://orcid.org/0000-0003-0784-8859)
- Jing Song (ORCID: https://orcid.org/0000-0002-1810-2254)
Institutions
- Hubei University of Arts and Science (CN)
- Xiangyang Central Hospital (CN)
Publication Details
- Journal
- Immunopharmacology and Immunotoxicology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1080/08923973.2025.2470344
- Citations
- 3
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 3.14